Avid Bioservices Inc (CDMO)

[entdoc]

tech, I think you are absolutely right that the SK comments on which I asked here for clarification were related to front line NSCLC. I appreciate you straightening me out on that, as requested. It also appears that "central reads" vs. "domestic reads" implies a difference between foreign and US test sites in that instance...an implication only. Applying the comments to pancreatic trials does not make sense. Remember, I stated up front that I needed clarification on what my notes implied, and received that clarification from you and Nuke and FTM. At this point a hypothesis that the snafu involved foreign testing sites or techniques is reassonable, but, as stated, is only a hypothesis. Appreciate the input.